

Protocol for Lofexidine Approved January 2022

Background:

Medically supervised opioid withdrawal, also known as detoxification, involves the administration of

medication to reduce the severity of withdrawal symptoms that occur when an opioiddependent patient stops using opioids

Lofexidine is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Criteria for Approval:

Patient meets ALL the following:

- 1. Patient is ≥18 years old
- 2. Diagnosis of opioid use disorder
- Patient is currently undergoing or is scheduled to undergo abrupt opioid discontinuation
- 4. Medication is prescribed by or in consultation with a provider specializing in pain management or addiction treatment
- 5. Patient has no history of congenital long QT syndrome; or will use lofexidine with caution
- 6. Medication is prescribed in accordance with Food and Drug Administration (FDA) established indication and dosing regimens or in accordance with medically appropriate off-label indication and dosing according to American Hospital Formulary Service, Micromedex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs (Lexicomp), national guidelines, or other peer reviewed evidence

Initial Approval:

14 days per episode of treatment (224 total tablets)

Dosing:

Three 0.18 mg tablets taken orally four times daily for 7 days

Approvable for a maximum of 224 tablets per 14-day supply for a 1-month period

Quantity Level Limit:

Aetna Better Health of New Jersey



Maximum dose 0.72 mg/dose (4 tablets) or 2.88 mg/day (16 tablets per day) or 224 tablets

References:

- 1. Lucemyra® [prescribing information]. US WorldMeds, LLC, 4441 Springdale Road, Louisville, KY 40241
- 2. Clinical Pharmacology® Gold Standard Series [Internet database]. Tampa FL. Elsevier 2019. Updated periodically
- 3. Sevarino KA. Medically supervised opioid withdrawal during treatment for addiction. UpToDate. Updated August 18, 2020. https://www.uptodate.com/contents/medically-supervised-opioid-withdrawal-duringtreatment-for-addiction Accessed November 12, 2021